stoxline Quote Chart Rank Option Currency Glossary
  
NRx Pharmaceuticals, Inc. (NRXP)
0.4989  -0.031 (-5.87%)    03-28 12:30
Open: 0.48
High: 0.5399
Volume: 904,581
  
Pre. Close: 0.53
Low: 0.4545
Market Cap: 46(M)
Technical analysis
2024-03-28 12:19:41 PM
Short term     
Mid term     
Targets 6-month :  0.65 1-year :  0.85
Resists First :  0.55 Second :  0.73
Pivot price 0.51
Supports First :  0.28 Second :  0.23
MAs MA(5) :  0.52 MA(20) :  0.53
MA(100) :  0.42 MA(250) :  0.43
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  35.2 D(3) :  37.4
RSI RSI(14): 50.6
52-week High :  1.2 Low :  0.22
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NRXP ] has closed above bottom band by 47.2%. Bollinger Bands are 38.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.55 - 0.55 0.55 - 0.56
Low: 0.5 - 0.51 0.51 - 0.51
Close: 0.53 - 0.53 0.53 - 0.53
Company Description

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Headline News

Thu, 28 Mar 2024
NRx Pharmaceuticals announces reverse stock split By Investing.com - Investing.com Australia

Thu, 28 Mar 2024
NRx Pharmaceuticals announces reverse stock split to maintain Nasdaq listing (NASDAQ:NRXP) - Seeking Alpha

Thu, 28 Mar 2024
NRx Pharmaceuticals reports progress and outlook - Investing.com India

Thu, 28 Mar 2024
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and ... - PR Newswire

Thu, 28 Mar 2024
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing - Yahoo Finance

Tue, 26 Mar 2024
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 92 (M)
Shares Float 58 (M)
Held by Insiders 31.1 (%)
Held by Institutions 4.4 (%)
Shares Short 2,710 (K)
Shares Short P.Month 2,870 (K)
Stock Financials
EPS -0.5
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.08
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -109 %
Return on Equity (ttm) -682.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.36
Qtrly Earnings Growth 0 %
Operating Cash Flow -27 (M)
Levered Free Cash Flow -15 (M)
Stock Valuations
PE Ratio -1.02
PEG Ratio 0
Price to Book value -6.33
Price to Sales 0
Price to Cash Flow -1.75
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android